Posted in | Nanobusiness

Nanostart-held Curiox Biosystems Wins Emerging Company Award

Published on March 14, 2010 at 11:15 PM

Nanostart-held Curiox was awarded "Emerging Company of the Year 2010 in Asia Pacific", on 12th March, by BioSpectrum Asia. BioSpectrum Asia is a leading B2B media platform covering the life sciences industry in the Asia Pacific region.

Curiox and other Asia Pacific companies were assessed on the basis of their achievements and potential for future growth to determine companies that shall emerge as industry leaders, in the biomedical science and biotechnology sectors, in the coming decade. BioSpectrum’s team of industry experts evaluated all aspects of the organizations’ performance and public profile, prior to nominating Curiox as the winner of the award in the sector biomedical sciences. The award was given to five more companies from other sectors in life sciences and medical technologies.

Curiox’s "Emerging Company of the Year" award comes hot on the heels of Curiox’s LabAutomation2010 "Innovation AveNEW" award, earlier this year; as one of the industry’s most innovative laboratory automation technology. This magnitude of worldwide industry acceptance and excitement for is welcomed by the young Singaporean start-up Curiox; and comes at a crucial time as Curiox begins to expand its products to overseas markets.

“It is truly an honour to be selected with top companies in Asia who have been around much longer than Curiox. These awards demonstrate to our customers, partners and competitors that our DropArray™ technology is truly innovative, and is recognized by industry experts (on a global scale) to be beneficial and potentially disruptive to the laboratory automation industry,” comments Curiox’s CEO Dr Namyong Kim.

Curiox's patent-pending DropArray™ technology provides a next-generation “wall-less” microtiter platform, and complimentary washing instrument, to provide researchers with better quality of data, 10 - 50 times savings in sample and reagent consumption, and up to 60 % assay time reduction. Additionally, DropArray™ technology promotes integration with liquid handling systems by maintainaining reproducibility and compatibility with existing microtiter plate detection systems.

Curiox Biosystems intends to penetrate the United States, European and Japanese laboratory markets this year through strategic partnerships and distributors.

According to BioSpectrum Asia, it has a readership of over 150,000 (including print magazine, online-edition and website) of which a large majority represent key decision makers in the Pharma and Biotech industry.

The Nanostart Singapore Early Stage Venture Fund I holds almost 19% in Curiox Biosystems.

Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. .

Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox’s patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time. The company is located in Singapore, the biomedical hub of Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore’s Agency for Science, Technology and Research (A*STAR).

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit